PCDHGC5

Across TCGA pan-cancer cohorts, PCDHGC5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PCDHGC5 data layer compared with 27 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher PCDHGC5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHGC5 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ESCA, SKCM, and BLCA are the cancer types where PCDHGC5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.213	0.915	.005	9	view →
SKCM	DFS	Median	II,III,IV	0.633	0.244	.016	9	view →
BLCA	OS	Median	III,IV	0.195	0.684	.010	6	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PCDHGC5–ESCA (OS)

Open the ESCA breakdown →